Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02869438 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 233
- Enrollment target
NCT02869438 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 233 participants.
The verdict
NCT02869438, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 233 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the onset and maintenance of effect of benralizumab on lung function, blood eosinophils, asthma control metrics and quality of life during 12-week treatment in patients with uncontrolled, severe asthma with eosinophilic inflammation. A subset of patients will take part in body plethysmography substudy to further investigate the effect on lung function.
Interventions
- OTHER Placebo
- DRUG Benralizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 233 participants |
| Start Date | 2016-11-09 |
| Est. Completion | 2018-08-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02869438
The ClinicalTrials.gov registry entry for NCT02869438 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 233 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02869438 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02869438 about?
NCT02869438 is a clinical study titled "A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation". The purpose of this study is to investigate the onset and maintenance of effect of benralizumab on lung function, blood eosinophils, asthma control metrics and quality of life during 12-week treatment in patients with uncontrolled, severe asthma with eosinophilic inflammation. A subset of patients w...
What is the current status of trial NCT02869438?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 233 participants. The study started on 2016-11-09. Estimated completion is 2018-08-01.
What interventions are being tested in trial NCT02869438?
The interventions under investigation include: Placebo (OTHER), Benralizumab (DRUG).
Who is sponsoring clinical trial NCT02869438?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.